Interleukin-21 in chronic inflammatory diseases

BioFactors

Volumn 39, Issue 4, 2013, Pages 368-373

  Sarra, Massimiliano ^a   Pallone, Francesco ^a   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Autoimmunity; CD4; IL 21; Inflammation

Indexed keywords

INTERLEUKIN 21; INTERLEUKIN 21 INHIBITOR; RECOMBINANT CYTOKINE; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ATOPIC DERMATITIS; B LYMPHOCYTE DIFFERENTIATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CHRONIC INFLAMMATION; CHRONIC INFLAMMATORY DISEASE; CYTOKINE PRODUCTION; HUMAN; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; MEMORY CELL; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; GASTROENTERITIS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 1; GASTROENTERITIS; HUMANS; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 84881620254     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1105     Document Type: Review

References (50)

1. Spolski, R., and Leonard, W. J. (2008) Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26, 57-79.
2. Spolski, R., and Leonard, W. J. (2010) IL-21 and T follicular helper cells. Int. Immunol. 22, 7-12.
3. Sarra, M., Cupi, M. L., Pallone, F., and Monteleone, G. (2012) Interleukin-21 in immune and allergic diseases. Inflamm. Allergy Drug.Targets 11, 313-319.
4. Kaser, A., Zeissig, S., and Blumberg, R. S. (2010) Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573-621.
5. Monteleone, G., Monteleone, I., Fina, D., Vavassori, P., Del Vecchio Blanco, G., et al. (2005) Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 128, 687-694.
6. Rovedatti, L., Kudo, T., Biancheri, P., Sarra, M., Knowles, C. H., et al. (2009) Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 58, 1629-1636
7. Sarra, M., Monteleone, I., Stolfi, C., Fantini, M. C., Sileri, P., et al. (2010) Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm. Bowel Dis. 16, 1332-1339.
8. Caruso, R., Fina, D., Peluso, I., Fantini, M. C., Tosti, C., et al. (2007) IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J. Immunol. 178, 5957-5965.
9. Fina, D., Sarra, M., Caruso, R., Del Vecchio Blanco, G., Pallone, F., et al. (2008) Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 57, 887-892.
10. Sarra, M., Cupi, M. L., Monteleone, I., Franzè, E., Ronchetti, G., et al. (2013) IL-15 positively regulates IL-21 production in celiac disease mucosa. Mucosal, Immunol.6, 244-255.
11. Fina, D., Sarra, M., Fantini, M. C., Rizzo, A., Caruso, R., et al. (2008) Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134, 1038-1048.
12. Fantini, M. C., Rizzo, A., Fina, D., Caruso, R., Becker, C., et al. (2007) IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur. J. Immunol. 37, 3155-3163.
13. Nestle, F. O., Kaplan, D. H., and Barker, J. (2009) Psoriasis. N. Engl. J. Med. 361, 496-509.
14. Caruso, R., Botti, E., Sarra, M., Esposito, M., Stolfi, C., et al. (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat. Med. 15, 1013-1015.
15. He, Z., Jin, L., Liu, Z. F., Hu, L., Dang, E. L., et al. (2012) Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Br. J. Dermatol. 167, 191-193.
16. Sarra, M., Caruso, R., Cupi, M. L., Monteleone, I., Stolfi, C., et al. (2011) IL-21 promotes skin recruitment of CD4(+) cells and drives IFN-γ-dependent epidermal hyperplasia. J. Immunol. 186, 5435-5442.
17. Gedebjerg, A., Johansen, C., Kragballe, K., and Iversen, L. (2012) IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta Derm Venereol. doi: 10.2340/00015555-1440.
18. Jin, H., Oyoshi, M. K., Le, Y., Bianchi, T., Koduru, S., et al. (2009) IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J. Clin. Invest. 119, 47-60.
19. Lin, S. C., Chuang, Y. H., Yang, Y. H., and Chiang, B. L. (2011) Decrease in interleukin-21 in children suffering with severe atopic dermatitis. Pediatr. Allergy Immunol. 22, 869-875.
20. Doganci, A., Birkholz, J., Gehring, S., Puhl, A. G., Zepp, F., et al. (2013).In the presence of IL-21 human cord blood T cells differentiate to IL-10 producing Th1 but not Th17 or Th2 cells. Int. Immunol.25, 157-169.
21. Tsokos, G. C., Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110-2121.
22. Wong, C. K., Wong, P. T., Tam, L. S., Li, E. K., Chen, D. P., et al. (2010) Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease. J. Clin. Immunol. 30, 45-52.
23. Ozaki, K., Spolski, R., Ettinger, R., Kim, H. P., Wang, G., et al. (2004) Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173, 5361-5371.
24. Bubier, J. A., Bennett, S. M., Sproule, T. J., Lyons, B. L., Olland, S., et al. (2007) Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1110, 590-601.
25. Bubier, J.A., Sproule, T. J., Foreman, O., Spolski, R., Shaffer, D. J., et al. (2009) A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc. Natl. Acad. Sci. USA. 106, 1518-1523.
26. Herber, D., Brown, T. P., Liang, S., Young, D. A., Collins, M., et al. (2007) IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J. Immunol. 178, 3822-3830.
27. Rankin, A. L., Guay, H., Herber, D., Bertino, S. A., Duzanski, T. A., et al. (2012) IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J. Immunol. 188, 1656-1667.
28. Daneman, D. (2006) Type 1 diabetes. Lancet 367, 847-858.
29. Asano, K., Ikegami, H., Fujisawa, T., Nishino, M., Nojima, K., et al. (2007) Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum. Immunol. 68, 384-391.
30. McGuire, H. M., Vogelzang, A., Hill, N., Flodström-Tullberg, M., Sprent, J., et al. (2009) Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus. Proc. Natl. Acad. Sci. USA 106, 19438-1943.
31. Spolski, R., Kashyap, M., Robinson, C., Yu, Z., and Leonard, W. J. (2008) IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc. Natl. Acad. Sci. U S A. 105, 14028-14033.
32. McGuire, H. M., Walters, S., Vogelzang, A., Lee, C. M., Webster, K. E., et al. (2011) Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 60, 867-875.
33. Sutherland, A. P., Van Belle, T., Wurster, A. L., Suto, A., Michaud, M., et al. (2009) Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 58, 1144-1155.
34. Caprioli, F., Sarra, M., Caruso, R., Stolfi, C., Fina, D., et al. (2008) Autocrine regulation of IL-21 production in human T lymphocytes. J. Immunol. 180, 1800-1807.
35. Liu, S. M., Lee, D. H., Sullivan, J. M., Chung, D., Jäger, A., et al. (2011) Differential IL-21 signaling in APCs leads to disparate Th17 differentiation in diabetes-susceptible NOD and diabetes-resistant NOD.Idd3 mice. J. Clin. Invest. 121, 4303-4310.
36. Brandt, K., Bulfone-Paus, S., Foster, D. C., and Rückert, R. (2003) Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102, 4090-4098.
37. Van Belle, T. L., Nierkens, S., Arens, R., and von Herrath, M. G. (2012) Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity 36, 1060-1672.
38. Forte, G. I., Ragonese, P., Salemi, G., Scola, L., Candore, G., et al. (2006) Search for genetic factors associated with susceptibility to multiple sclerosis. Ann. N Y Acad. Sci. 1067, 264-269.
39. Tzartos, J. S., Craner, M. J., Friese, M. A., Jakobsen, K. B., Newcombe, J., et al. (2011) IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am. J. Pathol. 178, 794-802.
40. Jones, J. L., Phuah, C. L., Cox, A. L., Thompson, S. A., Ban, M., et al. (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119, 2052-2061.
41. Vollmer, T. L., Liu, R., Price, M., Rhodes, S., La Cava, A., et al. (2005) Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 174, 2696-2701.
42. Piao, W. H., Jee, Y. H., Liu, R. L., Coons, S. W., Kala, M., et al. (2008) IL-21 modulates CD4+ CD25+ regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 67, 37-46.
43. Hippen, K. L., Bucher, C., Schirm, D. K., Bearl, A. M., Brender, T., et al. (2012) Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood 119, 619-628.
44. Zhao, X. Y., Lv, M., Xu, L. L., Qian, X., and Huang, X. J. (2013) Donor Th17 cells and IL-21 may contribute to the development of chronic graft-versus-host disease after allogeneic transplantation. Eur. J. Immunol. 43, 838-850.
45. Bucher, C., Koch, L., Vogtenhuber, C., Goren, E., Munger, M., et al. (2009) IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood. 114, 5375-5384.
46. Oh, I., Ozaki, K., Meguro, A., Hatanaka, K., Kadowaki, M., et al. (2010) Altered effector CD4+ T cell function in IL-21R-/- CD4+ T cell-mediated graft-versus-host disease. J. Immunol. 185, 1920-1926.
47. Hashmi, M. H., and Van Veldhuizen, P. J. (2010) Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert. Opin. Biol. Ther. 10, 807-817.
48. Fröhlich, A., Kisielow, J., Schmitz, I., Freigang, S., Shamshiev, A. T., et al. (2009) IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324, 1576-1580.
49. Stolfi, C., Rizzo, A., Franzè, E., Rotondi, A., Fantini, M. C., et al. (2011) Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J. Exp. Med. 208, 2279-2290.
50. Spolski, R., Wang, L., Wan, C. K., Bonville, C. A., Domachowske, J. B., et al. (2012) IL-21 promotes the pathologic immune response to pneumovirus infection. J. Immunol. 188, 1924-1932.